A Unique Platform for Curing Coronavirus and Similar Lethal Diseases

Ben-Sasson Shmuel, HUJI, School of Medicine - IMRIC, Developmental Biology and Cancer Research
Reuveni Hadas, HUJI
  • Increased blood vessel permeability and vascular leak are a final common pathway in severe influenza and other fatal diseases, such as MERS, Ebola, Coronavirus and sepsis.
  • We have developed at the Hebrew U.- Hadassah Medical School( Prof. Shmuel (Muli) Ben-Sasson and his colleagues a novel biologics that tightens blood vessels and prevents vascular-leak related death.
  • Drug characterization and mode of action (MoA): The drug is a novel short peptide (only 5 amino acids in length), including several chemical modifications. This biologics was rationally designed to abrogate vascular permeability, based on molecular insights we gained. Its efficacy was demonstrated in a mouse model of sepsi.

Patent Status

Granted US 9,873,724

Contact for more information:

Keren-Or Amar
VP, Business Development, Healthcare
Contact ME: